Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.


Journal

Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741

Informations de publication

Date de publication:
08 2020
Historique:
received: 05 12 2019
accepted: 29 02 2020
pubmed: 20 3 2020
medline: 25 5 2021
entrez: 20 3 2020
Statut: ppublish

Résumé

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used analgesics due to their lack of addictive potential. However, NSAIDs have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. CYP2C9 polymorphisms influence metabolism and clearance of several drugs in this class, thereby affecting drug exposure and potentially safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for NSAIDs based on CYP2C9 genotype (updates at www.cpicpgx.org).

Identifiants

pubmed: 32189324
doi: 10.1002/cpt.1830
pmc: PMC8080882
mid: NIHMS1687646
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
CYP2C9 protein, human EC 1.14.13.-
Cytochrome P-450 CYP2C9 EC 1.14.13.-

Types de publication

Journal Article Meta-Analysis Practice Guideline Research Support, N.I.H., Extramural Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

191-200

Subventions

Organisme : NIGMS NIH HHS
ID : R24 GM061374
Pays : United States
Organisme : NIGMS NIH HHS
ID : R24 GM115264
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG010135
Pays : United States
Organisme : NIGMS NIH HHS
ID : R24 GM123930
Pays : United States

Informations de copyright

© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

Références

Drug Saf. 2012 Dec 1;35(12):1127-46
pubmed: 23137151
PLoS One. 2015 Mar 16;10(3):e0120403
pubmed: 25775139
Pharmacogenet Genomics. 2014 Feb;24(2):113-7
pubmed: 24322170
Mil Med. 2017 Mar;182(3):e1709-e1712
pubmed: 28290947
J Clin Invest. 2006 Jan;116(1):4-15
pubmed: 16395396
Clin Pharmacol Ther. 2017 Sep;102(3):397-404
pubmed: 28198005
Clin Pharmacol Ther. 2017 Oct;102(4):611-622
pubmed: 28710775
Drug Metab Dispos. 2005 Jun;33(6):749-53
pubmed: 15764711
Postgrad Med J. 2004 Feb;80(940):107-9
pubmed: 14970301
PLoS One. 2007 Sep 05;2(9):e840
pubmed: 17786211
Clin Pharmacokinet. 1998 Nov;35(5):361-90
pubmed: 9839089
Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):476-80
pubmed: 21726410
Pharmacogenetics. 2002 Apr;12(3):251-63
pubmed: 11927841
Mol Phylogenet Evol. 2018 Aug;125:204-212
pubmed: 29631055
Clin Pharmacol Ther. 2005 Jun;77(6):479-85
pubmed: 15961979
Clin Pharmacol Ther. 2014 Nov;96(5):542-8
pubmed: 25099164
Am J Med. 2001 Feb 19;110 Suppl 3A:20S-7S
pubmed: 11173046
Pharmacogenomics. 2015;16(9):939-48
pubmed: 26122864
Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):43-50
pubmed: 23723142
Arch Pharm Res. 2015 Jun;38(6):1232-7
pubmed: 25712887
Mol Diagn Ther. 2007;11(2):123-8
pubmed: 17397249
Clin Pharmacol Ther. 2005 Sep;78(3):309-10
pubmed: 16153401
Am J Kidney Dis. 2005 Mar;45(3):531-9
pubmed: 15754275
Clin Pharmacol Ther. 2004 Aug;76(2):119-27
pubmed: 15289789
Thromb Haemost. 2003 Jul;90(1):161-2
pubmed: 12876643
Eur J Clin Pharmacol. 2009 Apr;65(4):365-75
pubmed: 19031075
Lancet. 2013 Aug 31;382(9894):769-79
pubmed: 23726390
Eur J Clin Pharmacol. 2003 Apr;58(12):791-4
pubmed: 12698304
Circulation. 2011 May 24;123(20):2226-35
pubmed: 21555710
Pharm Res. 2009 Apr;26(4):822-35
pubmed: 19082874
Gut. 2006 Dec;55(12):1731-8
pubmed: 16687434
Br J Sports Med. 2011 Feb;45(2):85-90
pubmed: 19666628
Thromb Haemost. 2004 Jan;91(1):95-101
pubmed: 14691574
Annu Rev Med. 2010;61:17-33
pubmed: 20059330
Pharmacogenomics J. 2009 Aug;9(4):283-90
pubmed: 19381162
Pharmacogenetics. 2003 Aug;13(8):473-80
pubmed: 12893985
Circulation. 2006 Sep 5;114(10):1028-35
pubmed: 16943394
Drug Metab Dispos. 2005 Nov;33(11):1567-75
pubmed: 16118328

Auteurs

Katherine N Theken (KN)

Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Craig R Lee (CR)

Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.

Li Gong (L)

Department of Biomedical Data Science and Department of Medicine, Stanford University, Stanford, California, USA.

Kelly E Caudle (KE)

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Christine M Formea (CM)

Department of Pharmacy and Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Department of Pharmacy and Intermountain Precision Genomics, Intermountain Healthcare, Salt Lake City, Utah, USA.

Andrea Gaedigk (A)

Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

Teri E Klein (TE)

Department of Biomedical Data Science and Department of Medicine, Stanford University, Stanford, California, USA.

José A G Agúndez (JAG)

University Institute of Molecular Pathology Biomarkers, UEx. ARADyAL Instituto de Salud Carlos III, Cáceres, Spain.

Tilo Grosser (T)

Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH